Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — Investor Presentation (May 2018)

61 slides from Anavex Life Sciences's investor presentation, May 2018

  1. Slide 1: May 2018 Corporate Presentation

    Slide 1: May 2018 Corporate Presentation

    May 2018 Corporate Presenta2on Christopher U Missling, PhD President & CEO Nasdaq: AVXL

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presenta2on contains forward-looking statements made within the meaning of the Private Securi2es Li2ga2on Reform Act of 1995 by Anavex® Life Sciences Corp. and its representa2ves. These statements can be iden2fied by introductory words such as “expects,” “plans,” “intends,” “believes

  3. Slide 3: Novel Target, New Approach to Treating CNS

    Slide 3: Novel Target, New Approach to Treating CNS

    Novel Target, New Approach to Trea2ng CNS Anavex u2lizes precision gene2c medicine to treat severe and devasta2ng neurological disorders. Anavex is focusing on rare diseases with no available therapy (Re] syndrome) and high risk CNS pa2ent popula2ons (Alzheimer’s disease, Parkinson’s disease) 3

  4. Slide 4: Summary

    Slide 4: Summary

    Summary Focus Finding effec2ve treatments for neurodevelopmental and neurodegenera2ve diseases, areas of high unmet need Mechanism Sigma-1 Receptor (S1R) targe2ng cellular homeostasis Approach Applying precision medicine to CNS ANAVEX®2-73, orally available S1R agonist with strong IP (COM 2033) and h

  5. Slide 5: Identification of Gene Signature from ANAVEX 2-73 Patients

    Slide 5: Identification of Gene Signature from ANAVEX 2-73 Patients

    Iden2fica2on of Gene “Signature” from ANAVEX®2-73 Pa2ents ANAVEX®2-73 Phase 2a clinical trial Corresponding approach to ANAVEX®2-73 treatment oncology precision medicine NOW: Gene2c signatures of the strongest responders to ANAVEX®2-73 5

  6. Slide 6: Portfolio of Compounds Varying in Sigma-1 Receptor Binding Activities

    Slide 6: Portfolio of Compounds Varying in Sigma-1 Receptor Binding Activities

    Pornolio of Compounds Varying in Sigma-1 Receptor Binding Ac2vi2es CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 *RETT SYNDROME ANAVEX®2-73 ALZHEIMER’S DISEASE PARKINSON’S DISEASE *INFANTILE SPASMS FRAGILE X ANGELMAN’S *FRONT. DEMENTIA (FTD) ANAVEX®3-71 (AF710B) ALZHEIMER’S DISEASE PARKINSON’S DISEA

  7. Slide 7: ANAVEX 2-73 is a S1R Agonist and Activates the Sigma-1 Receptor

    Slide 7: ANAVEX 2-73 is a S1R Agonist and Activates the Sigma-1 Receptor

    ANAVEX®2-73 is a S1R Agonist and Ac2vates the Sigma-1 Receptor S1R is an integral membrane protein involved in cellular homeostasis which targets restora2on of neuroplas2city and cellular stress response2,3 S1R deficiency accelerates Endogenous S1R agonists ac2vate the Sigma-1 Receptor in situa2on di

  8. Slide 8: Sigma-1R Agonists MoA: Restoring Homeostasis

    Slide 8: Sigma-1R Agonists MoA: Restoring Homeostasis

    Sigma-1R Agonists MoA: Restoring Homeostasis ANAVEX®2-73 Sigma-1R helping / Restoring Homeostasis s2mula2ng own body to regain func2onality Su et al., Trends Pharmacol Sci. 2016 Villard et al., J. Psychopharmacol. 2011 [σ1 Antagonist] Source: Adapted from Miki et al, Dec 9. doi: 10.1111/neup.12080 N

  9. Slide 9: ER-Mitochondrial Axis Membrane (MAM) in Neurodegenerative Diseases

    Slide 9: ER-Mitochondrial Axis Membrane (MAM) in Neurodegenerative Diseases

    Endoplasmic Re2culum (ER) -Mitochondrial Axis Membrane (MAM) is Key Area Involved in Neurodegenera2ve Diseases Common Cellular Processes in Neurodegenera2ve Diseases P. Gómez-Suaga Cell Death Dis. 2018 Mar; 9(3): 337. 9

  10. Slide 10: Sigma-1 Receptor Restores MAM Association

    Slide 10: Sigma-1 Receptor Restores MAM Association

    Sigma-1 Receptor Restores MAM Associa2on Normal condi2on Disease condi2on S1R ANAVEX®2-73 Miller et al. Trends Neurosci., 2016; Lahmy et al. Neuropsychopharmacol., 2013 • Normally quiescent, S1Rs become ac2vated during periods of cellular stress • ANAVEX®2-73 is well-posi2oned to enhance this respon

  11. Slide 11: Sigma-1R Translocates to Play a Role in Gene Transcription

    Slide 11: Sigma-1R Translocates to Play a Role in Gene Transcription

    Sigma-1R Translocates to Play a Role in Gene Transcrip2on: Func2onal Connec2on Between Cell Body and DNA Sigma-1R Ac2ve in the Cell Body The Sigma-1R is mainly expressed in the cell body at the MAM Mouse re2nal ganglion cell illuminated by Thy-1 driven GFP; immunostaining of S1R in red. Scale = 50 μ

  12. Slide 12: Overview ANAVEX 2-73 Clinical Trials

    Slide 12: Overview ANAVEX 2-73 Clinical Trials

    Overview ANAVEX®2-73 Clinical Trials ANAVEX®2-73-001 Study: • Randomized, double-blind, placebo- Popula2on PK, i.e. non- controlled Phase 1 (oral) linear mixed effect • Single ascending dose (SAD) (NLME) modeling, non- • 22 healthy subjects compartmental analysis and formal concept analysis (FCA) and

  13. Slide 13: Using Precision Medicine to Increase Clinical Trial Success Rate

    Slide 13: Using Precision Medicine to Increase Clinical Trial Success Rate

    Using Precision Medicine to Increase Clinical Trial Success Rate +38% +64% Thomas DW et al. Clinical Development Success Rates 2006-2015. BIO Industry Analysis 13

  14. Slide 14: Rett Syndrome: A Devastating Monogenic Disorder

    Slide 14: Rett Syndrome: A Devastating Monogenic Disorder

    Re] Syndrome (RTT): A Devasta2ng Monogenic Disorder Rare gene2c postnatal progressive neurodevelopmental disorder § Re] syndrome (RTT) is caused by spontaneous (de novo) muta2on in the MECP2 gene located on the X chromosome § For males the gene muta2on is lethal since males have only one X chromosom

  15. Slide 15: MECP2 is Mutated in Rett Syndrome Leading to Loss of Neuronal Function

    Slide 15: MECP2 is Mutated in Rett Syndrome Leading to Loss of Neuronal Function

    MECP2 is Mutated in Re] Syndrome Leading to Loss of Neuronal Func2on and Loss of BDNF § MECP2 is a calcium dependent gene, affects dendri2c spine development and necessary for other gene expressions, including BDNF § Loss of MECP2 func2on alters excitatory/inhibitory synap2c balance § MECP2 func2on r

  16. Slide 16: ANAVEX 2-73 Regulates Gene Expression and Restores BDNF Levels

    Slide 16: ANAVEX 2-73 Regulates Gene Expression and Restores BDNF Levels

    ANAVEX®2-73 Regulates Gene Expression and Restores BDNF Levels p<0.05 ANAVEX®2-73 fully restores BDNF expression levels in the hippocampus in the Fmr1 KO mouse model (p<0.05, KO vehicle vs. KO ANAVEX®2-73) Presented at An<epilep<c Drug Trials XIV 2017 Conference 16

  17. Slide 17: ANAVEX 2-73 Significantly Reduces Impairment in Mutated MECP2 Mouse Model

    Slide 17: ANAVEX 2-73 Significantly Reduces Impairment in Mutated MECP2 Mouse Model

    ANAVEX®2-73 Significantly Reduces Impairment in Mutated MECP2 Re] Syndrome Mouse Model Clasping at 8 weeks 100 90 p<0.001 80 Normal Impaired *** Clasping Hindlimbs (%) 70 60 50 p<0.05 40 * 30 20 10 0 Mecp2_WT Vehicle Mecp2_HET Vehicle Mecp2_HET AV2-73 (10 mg/kg) Mecp2_HET AV2-73 (30 mg/kg) 100 Claspi

  18. Slide 18: Significant Improvement in Multiple Movement Impairments

    Slide 18: Significant Improvement in Multiple Movement Impairments

    Significant Improvement in Mul2ple Movement Impairments Rotarod Neurocube Startle Motor Coordina2on and Planorm that employs computer Wild type (WT) mice have a exercise capacity are assessed: vision to detect changes in gait higher startle response compared ANAVEX®2-73 treated mice took geometry and

  19. Slide 19: ANAVEX 2-73 Phase 2 Rett Syndrome Study Design

    Slide 19: ANAVEX 2-73 Phase 2 Rett Syndrome Study Design

    ANAVEX®2-73 Phase 2 Re] Syndrome Study Design Randomized, Double-Blind, Placebo-Controlled Study of ANAVEX®2-73 4 weeks 4 weeks 8 weeks Baseline Dose Titra2on Full Dose Observa2on Treatment AV 2-73: AV 2-73: Low dose Low dose 12 Weeks Ini2al N<90 Randomiza2on to 1 of 3 arms AV 2-73: AV 2-73: Volunta

  20. Slide 20: Parkinson's Disease Dementia: A Devastating Dementia Disorder

    Slide 20: Parkinson's Disease Dementia: A Devastating Dementia Disorder

    Parkinson’s Disease Demen2a (PDD): A Devasta2ng Demen2a Disorder Parkinson’s disease demen2a: Demen2a occurs a year or more awer the onset of motor symptoms § Parkinson's disease is a fairly common neurological disorder in older adults, es2mated to affect nearly 2 percent of those older than age 65 §

  21. Slide 21: ANAVEX 2-73 Targets MAM in Parkinson's Pathogenesis

    Slide 21: ANAVEX 2-73 Targets MAM in Parkinson's Pathogenesis

    ANAVEX®2-73 Targets MAM to Reduce Cellular Damage: How it May Work in Parkinson’s Pathogenesis MAM: Mitochondria-Associated Membrane § A specific type of phosphorylated α-syn aggregate leads to neurotoxicity in PD § These aggregates co- localize with MAM § They induce mitochondrial toxicity, oxida2ve

  22. Slide 22: Parkinson's Disease Model: ANAVEX 2-73 Improves Motor Behaviors

    Slide 22: Parkinson's Disease Model: ANAVEX 2-73 Improves Motor Behaviors

    Parkinson’s Disease Model: ANAVEX®2-73 Significantly Improves Motor Behaviors § ANAVEX®2-73 was evaluated in the 6-OHDA Parkinson’s disease model § ANAVEX®2-73 significantly improves motor behaviors compare to a double- blind control group (saline) § (A) Spontaneous rota2on ac2vity § (B) Cylinder test

  23. Slide 23: ANAVEX 2-73 Normalizes Pathophysiological Biomarkers

    Slide 23: ANAVEX 2-73 Normalizes Pathophysiological Biomarkers

    ANAVEX®2-73 Normalizes Pathophysiological Biomarkers ANAVEX®2-73 reduces microglia over-ac2va2on ANAVEX®2-73 restores dopaminergic neurons ANAVEX®2-73 significantly decreased the expression of ANAVEX®2-73 significantly increases tyrosine- CD68 (marker of ac2vated microglia) in the substan2a hydroxylas

  24. Slide 24: ANAVEX 2-73-003 Alzheimer's Study: Safety and Tolerability through 109 weeks

    Slide 24: ANAVEX 2-73-003 Alzheimer's Study: Safety and Tolerability through 109 weeks

    ANAVEX®2-73-003 Alzheimer’s Disease Study: Con2nued Favorable Safety and Tolerability through 109 weeks PART A PART B 003 Study## 002 Study# 002 Study# 1. Es2mate the maximal tolerated 1. Establish con2nued safety Establish con2nued safety and dose (MTD) and tolerability of ANAVEX tolerability of AN

  25. Slide 25: Primary and Secondary Endpoints Met in Phase 2a Alzheimer's Trial

    Slide 25: Primary and Secondary Endpoints Met in Phase 2a Alzheimer's Trial

    ANAVEX®2-73 Primary and Secondary Endpoints Met in Phase 2a Clinical Trial of Mild-to-Moderate Alzheimer’s Pa2ents § Phase 2a results demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile at doses between 10mg and 50mg of oral daily ANAVEX®2-73 § Primary e

  26. Slide 26: ANAVEX 2-73 Primary Endpoint Safety Data

    Slide 26: ANAVEX 2-73 Primary Endpoint Safety Data

    ANAVEX®2-73 Primary Endpoint Safety Data measured to 57 weeks: § The most common adverse event (AE): mild dizziness § When pa2ents were first dosed with highest dose § Was transient and reversible § Consistent with Blood Brain Barrier (BBB) penetra2on § 98% of all AEs were mild or moderate and revers

  27. Slide 27: Secondary Endpoints: Consistent Improved Response

    Slide 27: Secondary Endpoints: Consistent Improved Response

    Secondary Endpoints: High ANAVEX®2-73 Concentra2on linked to Consistent Improved Response Across All Analytes and Periods ANAVEX®2-73 shows a consistent response across the 3 different 2mes frames: Part A1 [0-24h] Part A2 [24-264h] Part B [52 weeks] Immediate response Short-term response Long-term re

  28. Slide 28: Robust Dose(Concentration)/Response Effect of ANAVEX 2-73

    Slide 28: Robust Dose(Concentration)/Response Effect of ANAVEX 2-73

    Robust Dose(Concentra2on)/Response Effect of ANAVEX®2-73 Systema2c explora2on of the full data matrix using KEM® demonstrates consistent concentra2on-response rela2onship for 6 main exploratory endpoints: cogni2on, func2on and biomarker (MMSE, ADCS-ADL, EEG/ERPs) 54% High dose -> Improved response 97

  29. Slide 29: Relation between ANAVEX 2-73 Concentration and MMSE

    Slide 29: Relation between ANAVEX 2-73 Concentration and MMSE

    Rela2on between ANAVEX®2-73 Concentra2on and MMSE An increase of MMSE during 57 weeks is a rare event. A pa2ent receiving a higher concentra2on of ANAVEX2-73 has a 2.1-fold chance of improving its MMSE Low Medium High High Concentra2on MMSE increases Increasing Decreasing Low Concentra2on MMSE decre

  30. Slide 30: Relation between ANAVEX 2-73 Concentration and ADCS-ADL

    Slide 30: Relation between ANAVEX 2-73 Concentration and ADCS-ADL

    Rela2on between ANAVEX®2-73 Concentra2on and ADCS-ADL An increase of ADCS-ADL during 57 weeks is a rare event. A pa2ent receiving a higher concentra2on of ANAVEX2-73 has a 1.6-fold chance of improving its ADCS-ADL Low Medium High High Concentra2on ADCS-ADL increases High Medium Low Low Concentra2on

  31. Slide 31: Patient Cohort with Cognitive and Functional Improvements

    Slide 31: Patient Cohort with Cognitive and Functional Improvements

    Pa2ent Cohort with Cogni2ve and Func2onal Improvements at 57 Weeks: RetainedMMSE Response at 109 and ADCS-ADL Weeks remained steady over 27 months (109 weeks) 30 28 26 24 101009 22 101011 MMSE 20 101013 18 16 101014 14 102006 12 102010 10 0 5 17 31 41 53 57 70 83 96 109 Weeks 80 75 70 65 101009 ADCS

  32. Slide 32: MMSE and ADCS-ADL Significantly Different to SoC AD

    Slide 32: MMSE and ADCS-ADL Significantly Different to SoC AD

    MMSE Δ and ADCS-ADL Δ Significantly Different to SoC AD 1.8 MMSE points difference 4 ADCS-ADL points difference 1.8 MMSE points 4 ADCS-ADL points improvement to historical improvement to historical control (SoC)# at week 57 control (SoC)# at week 57 (p=0.0164) (p=0.0186) § Comparison to historical contr

  33. Slide 33: Summary

    Slide 33: Summary

    Summary § ANAVEX®2-73 appears to have a favorable safety profile and to be generally well tolerated § ANAVEX®2-73 has demonstrated efficacy in the clinic as well as in mul2ple preclinical disease models valida2ng the Sigma-1R mechanism of ac2on § Gene2c Signatures for those who respond best to ANAVEX®2

  34. Slide 34: Financial Position and Near Term Catalysts

    Slide 34: Financial Position and Near Term Catalysts

    Financial Posi2on and Near Term Catalysts § Cash (as of March 31, 2018): $25.7M; No debt § The company is well capitalized to achieve clinical readouts þ Orphan Drug Designa2ons granted for the following indica2ons: Re] syndrome, Infan2le spasms and Frontotemporal demen2a þ Phase 2a – Reported 109 w

  35. Slide 35: Anavex Life Sciences Expertise

    Slide 35: Anavex Life Sciences Expertise

    Anavex Life Sciences Exper2se Management Team Christopher U. Missling, Emmanuel O Fadiran, Stephan Toutain, Paul Vancutsem, Daniel Klamer, PhD RPh, PhD MS, MBA DVM, PhD PhD President & CEO SVP of Regulatory Affairs SVP of OperaIons VP of Preclinical VP of Business Development Development & ScienIfic S

  36. Slide 36: Contact Us

    Slide 36: Contact Us

    Contact Us Corporate Office: Shareholder & Media Rela2ons: Anavex™ Life Sciences Corp. Solebury Trout 51 West 52nd Street, 7th floor mpurcell@soleburytrout.com New York, NY 10019 www.anavex.com 1-844-689-3939 NASDAQ: AVXL ANAVEX is a trademark of Anavex Life Sciences Corp. 36

  37. Slide 37: Back Up Slides

    Slide 37: Back Up Slides

    Back Up Slides NWanavex »

  38. Slide 38: Comprehensive Phase 2a Patient Characterization

    Slide 38: Comprehensive Phase 2a Patient Characterization

    Comprehensive Phase 2a Pa2ent Characteriza2on to Iden2fy Ac2onable Phase 2/3 Clinical Trial Parameters MMSE ADCS-ADL COGSTATE MMSE EEG/ERP Scores ADCS-ADL HAM-D Baseline COGSTATE Scores EEG/ERP Popula2on PK HAM-D Evolu<on == Clinical DNA RNA Gut assessment, FGS FGS Microbiota Vital signs, co-medica<

  39. Slide 39: Example of a Gene Signature: BDNF Polymorphism Val66met

    Slide 39: Example of a Gene Signature: BDNF Polymorphism Val66met

    Example of a Gene “Signature”: BDNF Polymorphism Val66met BDNF Val66met Polymorphism implicated in Neurodevelopmental and Neurodegenera2ve Disorders BDNF Val66met polymorphism directly correlates with: 1/3 of all pa2ents have this muta2on Higher seizure frequency Accelerated cogniIve decline and sev

  40. Slide 40: Targeted Genomic-Driven Clinical Trial Approach in Alzheimer's Disease

    Slide 40: Targeted Genomic-Driven Clinical Trial Approach in Alzheimer's Disease

    Example of a Targeted Genomic-Driven Clinical Trial Approach in Alzheimer’s Disease Boots EA et al., Neurology. 2017 May 30;88(22):2098-210 40 Brookmeyera R et al., Alzheimer’s & DemenYa. 2017 in press

  41. Slide 41: Patient Genomic Analysis: Genetic Mutations Linked to Alzheimer's

    Slide 41: Patient Genomic Analysis: Genetic Mutations Linked to Alzheimer's

    Pa2ent Genomic Analysis - Number of Associated Gene2c Muta2ons Linked to Alzheimer’s Disease have Increased GWAS = genome-wide associa2on studies Contribu2on of gene variants to the development of Alzheimer's disease has clinical implica2ons, including enhancing diagnos2c accuracy and providing targ

  42. Slide 42: Rare Disease Drug Discovery Approach

    Slide 42: Rare Disease Drug Discovery Approach

    Rare Disease Drug Discovery Approach: Higher Success Rate of Clinical Trials Expected 42

  43. Slide 43: Shift to Use Precision Medicine in Alzheimer's

    Slide 43: Shift to Use Precision Medicine in Alzheimer's

    Shiw to Use Precision Medicine to Break the No2on That Alzheimer’s is a Single Disease § Researchers are star2ng to combine gene2cs with lessons learned from the failed β amyloid-based clinical trials, not only to find new targets but also to stra2fy pa2ents § The view now is that the disease is more

  44. Slide 44: Examples of Continued Improvements and Reported Events

    Slide 44: Examples of Continued Improvements and Reported Events

    Examples of Con2nued Improvements and Reported Events ‘Therapeu2c Response’ during 57 Weeks PATIENT EVENTS: THERAPEUTIC RESPONSE UNEXPECTED 101001 MORE ALERT REGARDING SURROUNDINGS 101002 FEELS MUCH HAPPIER MAKING JOKES Examples of MMSE "Strong" Pa2ent Responders MUCH HAPPIER WHEN ATTENDING CLINIC A

  45. Slide 45: HAM-D: Reduction of Insomnia, Anxiety and other Symptoms

    Slide 45: HAM-D: Reduction of Insomnia, Anxiety and other Symptoms

    HAM-D: Reduc2on of Insomnia, Anxiety and other Symptoms Improved Items of HAM-D Scored Improvement Count in [%] Insomnia 8 29% Work and ac2vi2es 6 21% Anxiety (psychic and soma2c) 5 18% Agita2on 4 14% Depressed 4 14% Insight 3 11% Hypochondriasis 2 7% Loss of libido or other genital symptoms 2 7% Gu

  46. Slide 46: Robust Correlation of Cognition, Function and Behavior Response

    Slide 46: Robust Correlation of Cognition, Function and Behavior Response

    ANAVEX®2-73: Robust Correla2on of Cogni2on, Func2on and Behavior Response ANAVEX®2-73 Response cluster in a homogenous manner: Consistent response across mul2ple domains § Principal component analysis of the Δ sub-scores between week 31 and baseline for MMSE (MM), ADCS-ADL (AD), and HAM-D (HA) Good

  47. Slide 47: ANAVEX 2-73 Rescues Synaptic Networks

    Slide 47: ANAVEX 2-73 Rescues Synaptic Networks

    ANAVEX®2-73 Rescues Synap2c Networks and has Posi2ve Effect on Cogni2on and Behavior 1. ERP peak measures (P300): fundamental measures of synap2c network performance 2. ERP target detec2on task measures: direct measures of a]en2on, speed of brain ADCS-ADL: processing, and simple behavioral performanc

  48. Slide 48: Pre-Specified PK Sampling Protocol during Phase 2a

    Slide 48: Pre-Specified PK Sampling Protocol during Phase 2a

    Comprehensive Pre-Specified PK Sampling Protocol during Phase 2a Study Part A: IV (3/5 mg), Oral (30/50 mg) Part B: Oral (10 to 50 mg) Measures (hours) 012 68 12 18 24 012 68 12 18 24 48 72 120 192 264 48 72 120 192 264 Daily intake Period 1 Wash out Period 2 Part B: All pa2ents on ANAVEX®2-73 oral d

  49. Slide 49: Clearance of ANAVEX 2-73 Independent of given Dose

    Slide 49: Clearance of ANAVEX 2-73 Independent of given Dose

    Clearance of ANAVEX®2-73 Independent of given Dose Total average drug exposure over 2me AUC(0 to infinity) Area Under the Curve, 0-24h ANAVEX2-73 Treatment 49

  50. Slide 50: Reliable Inter-Individual Variability for Phase 2a Study

    Slide 50: Reliable Inter-Individual Variability for Phase 2a Study

    Confirmed Reliable Inter-Individual Variability (Dispersion) for the ANAVEX2-73 Phase 2a Study with 32 Pa2ent Cohort Real data -8 -8.5 -9 § Evalua2on of the dispersion -9.5 index of all the 32 pa2ent of the Phase 2a reveals that Dispersion index -10 -10.5 above any random sample of -11 -11.5 16 pa2en

  51. Slide 51: Alzheimer Disease Progression: Open-label vs Placebo-controlled

    Slide 51: Alzheimer Disease Progression: Open-label vs Placebo-controlled

    Alzheimer Disease Progression: Comparable cogni2ve decline in open-label studies as in placebo-controlled studies Progressive decline in cogni2on: Progressive decline in cogni2on: Open-label study with SoC# Double-blind placebo-controlled study with SoC## ADAS-Cog Change from baseline 52 weeks Place

  52. Slide 52: ANAVEX 2-73: Dose-Dependent Anti-Seizure Effects

    Slide 52: ANAVEX 2-73: Dose-Dependent Anti-Seizure Effects

    ANAVEX®2-73: Dose-Dependent An2-Seizure Effects Significant Seizure Reduc2on with ANAVEX®2-73 in Angelman Seizure Model ANAVEX 2-73 (10 mg/kg ip dosed daily for 14 days) Significant Seizure Reduc2on with ANAVEX®2-73 in both MES and PTZ-Induced Seizure Models 100 p=0.0065 90 80 MES-induced convulsions %

  53. Slide 53: Positive Preclinical Data in Parkinson's Disease

    Slide 53: Positive Preclinical Data in Parkinson's Disease

    Posi2ve Preclinical Data in Parkinson’s Disease ü At all doses tested ANAVEX®2-73 reduced novelty/stress-induced ac2vity while basal ac2vity levels were not significantly affected ü Mouse behavioral and motor pa]erns were completely normal; no signs of dystonia or stereotypic behaviors were observed ü

  54. Slide 54: Sigma-1 Receptor Activation and Neurodegenerative Diseases

    Slide 54: Sigma-1 Receptor Activation and Neurodegenerative Diseases

    Sigma-1 Receptor Ac2va2on and Neurodegenera2ve Diseases 54

  55. Slide 55: Novel Target: Sigma-1 Receptor

    Slide 55: Novel Target: Sigma-1 Receptor

    Novel Target: Sigma-1 Receptor Su et al., Trends Pharmacol Sci. 2016 55

  56. Slide 56: Confirmed Effects of Sigma-1 Receptor Activation

    Slide 56: Confirmed Effects of Sigma-1 Receptor Activation

    Confirmed Effects of Sigma-1 Receptor Ac2va2on … ü Synaptogenesis ü Restores Ca2+ imbalance ü Reduces Inflamma2on ü Reduces Oxida2ve stress ü Reduces Tau hyper-phosporyla2on ü Restores Mitochondrial dysfuncion ü Reduces Protein Misfolding … effects relevant in both neurodevelopmental as well as neurodeg

  57. Slide 57: ANAVEX 3-71 Decreases Hallmark Pathologies in Alzheimer's Model

    Slide 57: ANAVEX 3-71 Decreases Hallmark Pathologies in Alzheimer's Model

    ANAVEX®3-71 Significantly Decreases Hallmark Pathologies in 3xTg-Alzheimer’s Disease Model § 10 month-old 3xTg-AD and WT mice § administered i.p. with tap water or ANAVEX®3-71 (10 mcg/kg/ day) for 2 months 57 Source: Fisher et al., Neurodegenera<ve Diseases 2015 DOI: 10.1159/000440864

  58. Slide 58: Sigma-1 Receptor's Role in Regulating Gene Transcription

    Slide 58: Sigma-1 Receptor's Role in Regulating Gene Transcription

    Sigma-1 Receptor’s Role in Regula2ng Gene Transcrip2on Sigma-1 receptor agonist such as ANAVEX 2-73 S1R can translocate to the nuclear envelope where it binds emerin that in turn recruits barrier-to- autointegra2on factor (BAF) and histone deacetylase (HDAC) to form a complex with specific protein 3

  59. Slide 59: Pathological GSK-3β Activation can be Inhibited with ANAVEX 2-73

    Slide 59: Pathological GSK-3β Activation can be Inhibited with ANAVEX 2-73

    Pathological GSK-3β Ac2va2on can be Inhibited with ANAVEX®2-73 Lahmy et al., Neuropsychopharmacol., 2013 Ac2ve GSK-3β has been found in AD brains with neurofibrillary changes and an increase in tau hyperphosphoryla2on, neurodegenera2on and spa2al Injec2on of Aβ25-35 yields a hyper-inflammatory state t

  60. Slide 60: Sources: GlobalGenes.org, PhRMA, NIBR

    Slide 60: Sources: GlobalGenes.org, PhRMA, NIBR

    Sources: GlobalGenes.org1, PhRMA, NIBR 6060

  61. Slide 61: Neurodegenerative Diseases

    Slide 61: Neurodegenerative Diseases

    NEURODEGENERATIVE DISEASES The global cost of dementia is estimated to be US$ 818 billion More than 10 Million people are believed to have Parkinson's disease Economic burden of Alzheimer's disease (AD) care is estimated to reach $1.5 trillion by 2050 FDA has approved 4 drugs for AD that only tempor

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks